Amanda Pacheco

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Cooley advised Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein-coupled receptor (GPCR)-targeted radiopharmaceuticals to treat a broad range of solid tumors, on the formation of a strategic agreement with Eli Lilly to take forward Radionetics’ proprietary GPCR-targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million up-front cash payment. Additionally, Lilly obtained the exclusive right to acquire Radionetics for $1 billion upon conclusion of an exercise period.

Cooley advised Rooam, a contactless payment platform that integrates directly into existing point of sale systems without adding extra hardware, on its agreement to be acquired by American Express (NYSE: AXP), a globally integrated payments company providing customers with access to products, insights and experiences that enrich lives and build business success.

Cooley advised FutureGen Biopharmaceutical, an innovative biopharmaceutical company committed to providing high-quality innovative biologics for patients with cancer, immune diseases and other diseases, on its license agreement with AbbVie to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.

Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.